Metagenomic analysis of DNA viruses from posttransplant lymphoproliferative disorders by Dharnidharka, Vikas R et al.











See next page for additional authors
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs
Authors
Vikas R. Dharnidharka, Marianna B. Ruzinova, Chun-Cheng Chen, Priyanka Parameswaran, Harry
O'Gorman, Charles W. Goss, Hongjie Gu, Gregory A. Storch, and Kristine Wylie
Cancer Medicine. 2019;8:1013–1023.    |  1013wileyonlinelibrary.com/journal/cam4
Received: 13 September 2018 | Revised: 15 December 2018 | Accepted: 27 December 2018
DOI: 10.1002/cam4.1985
O R I G I N A L  R E S E A R C H
Metagenomic analysis of DNA viruses from posttransplant 
lymphoproliferative disorders
Vikas R. Dharnidharka1  | Marianna B. Ruzinova2 | Chun‐Cheng Chen3 |  
Priyanka Parameswaran1 | Harry O'Gorman1 | Charles W. Goss4 | Hongjie Gu4 |  
Gregory A. Storch5 | Kristine Wylie5,6
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original 
work is properly cited.
© 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
1Division of Pediatric 
Nephrology, Washington University School 
of Medicine, St Louis, MO, USA
2Department of Pathology and 
Immunology, Washington University 
School of Medicine, St Louis, MO, USA
3Department of Surgery, Washington 
University School of Medicine, St Louis, 
MO, USA
4Department of Biostatistics, Washington 
University School of Medicine, St Louis, 
MO, USA
5Division of Pediatric Infectious 
Diseases, Washington University School of 
Medicine, St Louis, MO, USA
6McDonnell Genome Institute, Washington 
University School of Medicine, St Louis, 
MO, USA
Correspondence
Vikas R. Dharnidharka, Division of 
Pediatric Nephrology, Hypertension and 
Pheresis, Washington University School of 




Funded through grant MC‐II‐2014‐394 
from Children's Discovery Institute, St. 
Louis MO  USA.
Abstract
Posttransplant lymphoproliferative disorders (PTLDs), 50%‐80% of which are 
strongly associated with Epstein‐Barr virus (EBV), carry a high morbidity and mor-
tality. Most clinical/epidemiological/tumor characteristics do not consistently asso-
ciate with worse patient survival, so our aim was to identify if other viral genomic 
characteristics associated better with survival. We extracted DNA from stored paraf-
fin‐embedded PTLD tissues at our center, identified viral sequences by metagenomic 
shotgun sequencing (MSS), and analyzed the data in relation to clinical outcomes. 
Our study population comprised 69 PTLD tissue samples collected between 1991 
and 2015 from 60 subjects. Nucleotide sequences from at least one virus were de-
tected by MSS in 86% (59/69) of the tissues (EBV in 61%, anelloviruses 52%, gam-
mapapillomaviruses 14%, CMV 7%, and HSV in 3%). No viruses were present in 
higher proportion in EBV‐negative PTLD (compared to EBV‐positive PTLD). In 
univariable analysis, death within 5 years of PTLD diagnosis was associated with 
anellovirus (P = 0.037) and gammapapillomavirus (P = 0.036) detection by MSS, 
higher tissue qPCR levels of the predominant human anellovirus species torque teno 
virus (TTV; P = 0.016), T cell type PTLD, liver, brain or bone marrow location. In 
multivariable analyses, T cell PTLD (P = 0.006) and TTV PCR level (P = 0.012) 
remained significant. In EBV‐positive PTLD, EBNA‐LP, EBNA1 and EBNA3C had 
significantly higher levels of nonsynonymous gene variants compared to the other 
EBV genes. Multiple viruses are detectable in PTLD tissues by MSS. Anellovirus 
positivity, not EBV positivity,was associated with worse patient survival in our se-
ries. Confirmation and extension of this work in larger multicenter studies is 
desirable.
K E Y W O R D S
anellovirus, Epstein-Barr virus, lymphoma, posttransplant lymphoproliferative disorders, viral infection
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1 |  BACKGROUND
Posttransplant lymphoproliferative disorders (PTLDs), an ab-
normal proliferation of lymphoid cells under posttransplant 
immunosuppression, are a major malignant complication of 
organ and tissue transplant.1-4 PTLDs have a high morbidity and 
5‐year mortality that exceeds 50%.3 About 50%‐80% of PTLD 
cases are strongly related to the oncogenic Epstein‐Barr virus 
(EBV).5 Cytomegalovirus seromismatch has been associated 
in some studies6,7 but not consistently. It is not known whether 
other viruses are also associated with PTLD. While recent mor-
tality rates have decreased with general medical advances and 
newer therapies,8,9 mortality remains high10 and graft failure is a 
significant complication of interventions.11 Though many prog-
nostic indices have been used to predict survival after PTLD, 
mortality after PTLD is not fully explained by these indices.12-14 
These indices vary considerably in their component prognos-
tic factors; they do not consistently include the same clinical, 
viral, epidemiologic or tumor characteristics. Therefore, host 
responses to EBV and the degree of overall immunosuppression 
have been studied as possible contributors to prognosis and out-
come, but still do not fully explain the outcomes.15-17
Our aim was to determine whether there were DNA vi-
ruses associated with EBV‐negative PTLD or PTLD out-
comes using metagenomic shotgun sequencing (MSS) of 
archived formalin‐fixed paraffin‐embedded (FFPE) tissue 
samples from PTLD patients. MSS is an approach that as-
sesses genomic material from host and microbes within a 
sample, allowing for the culture‐independent detection of 
microbes without a priori knowledge of which viral groups 
are present with a sample. Like genome‐wide association 
tools, MSS is a powerful tool for studying viruses in clinical 
samples because it allows evaluation of a comprehensive set 
of viruses simultaneously. In addition, MSS can provide ge-
nomic data that can be used to assess features or variants that 
may associate with virulence or pathogenicity. Our approach 
included the use of ViroCap™, a targeted sequence capture 
method that we developed recently to enhance detection of 
viral sequences by MSS.18 This improved methodology al-
lows us to thoroughly characterize the viruses associated 
with PTLD, and eventually study how EBV genome variants 
contribute to more severe presentations or worse outcomes. 
We can also study which viruses, if any, are associated with 
EBV‐negative PTLD. We undertook this genomic analysis 
because these newer technologies could lead to new informa-
tion and insights not found with other methods.
2 |  METHODS
This study was approved the Human Subjects Research 
Protection Office at Washington University School of 
Medicine.
2.1 | Tissue sample identification
We first identified through a search of our electronic medical 
records that all tissue blocks from PTLD cases available in 
the tissue archives of the Washington University School of 
Medicine Pathology Department. Tissue specimens of suf-
ficient quantity (as evaluated by hematopathologist MBR) 
were selected for nucleic acid extraction. We also identi-
fied 8 EBV‐negative control tissues (abdominal lymph 
nodes from cases of diverticulitis, prolapse, appendicitis or 
gunshot wound) and four positive EBV‐positive control tis-
sues that were either Hodgkin lymphoma or diffuse large B 
cell lymphoma (DLBCL) from immunocompetent patients 
in a nontransplant setting. Pathological and clinical co-
variates extracted for the PTLD specimens are described in 
Supplementary Methods.
2.2 | DNA extraction and MSS
DNA extraction methods are described in Supplementary 
Methods. We generated dual‐indexed sequencing librar-
ies from the DNA using the KAPA Low Throughput 
Library Construction Kit (KAPA Biosystems, Wilmington, 
Massachusetts). We pooled libraries and mixed them with the 
ViroCap™ targeted sequence capture probes (synthesized by 
Nimblegen®), which target and enrich genomes from a com-
prehensive set of vertebrate viruses to enhance sensitivity. 
Targeted sequence capture was carried out according to the 
manufacturer's instructions. We sequenced the enriched viral 
nucleic acids using the Illumina HiSeq 2000/2500 platform. 
We analyzed sequences using a pipeline adapted from the 
method previously described by us19 except that Burroughs 
Wheeler Alignment tool BWA MEM was used for the nu-
cleotide sequence alignments.20 To avoid false positives re-
sulting from index swapping during capture,21-23 in which the 
library‐specific indexes are transferred between libraries at a 
low frequency, we subtracted 0.1% of the total viral reads for 
each virus within a pool from each sample. This threshold 
was based on published studies21-23 and our experience with 
capture of dual‐indexed sequencing libraries.18 Samples with 
viral signal above or below that threshold were considered 
positive or negative, respectively, as a categorical variable. 
Sequences were manually reviewed to verify classification of 
herpesvirus and polyomavirus sequences.
2.3 | EBV variant analysis
For samples that were positive for EBV sequences, se-
quences were aligned to canonical EBV‐1 and EBV‐2 refer-
ence genomes (NCBI Reference Sequence: NC_007605.1 
and NC_009334.1). The depth and breadth of coverage 
were calculated using RefCov (http://gmt.genome.wustl.
edu/packages/refcov/), and alignments were reviewed 
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to determine EBV type. Samples in which >70% of the 
EBV‐1 genome represented in the sequencing data were 
included in subsequent comparative analysis. Variants 
compared to the reference EBV‐1 genome were identified 
using Varscan, a platform‐independent software tool de-
veloped at the McDonnell Genome Institute at Washington 
University to detect variants in genomic data.24 For vari-
ant analysis, nucleotide positions with <10× read depth 
were classified as unevaluable and excluded. Variants and 
coverage were manually reviewed using Tablet, a high‐per-
formance graphical viewer for metagenomic sequence as-
semblies and alignments.25
2.4 | Data submission
Submission of microbial sequencing data to the public 
Sequence Read Archive is in progress at the time of submis-
sion, and BioProject and SRS identifiers will be provided 
prior to publication.
2.4.1 | Polymerase chain reaction
Tissue specimens were tested by quantitative PCR assays 
for EBV and the predominant anellovirus species in hu-
mans, torque teno virus (TTV), alpha subtype. Details of the 
PCR assays are described in the Supplementary Methods.
2.4.2 | Statistical analyses
Details of the statistical analyses are in the Supplementary 
Methods.
3 |  RESULTS
3.1 | Subjects and samples
We identified 163 records in the Department of Pathology 
tissue archives, of which 69 specimens from 60 subjects 
from the period 1991‐2015 were adequate for analysis 
T A B L E  1  Study subject (n = 60) and sample (n = 69) characteristics
Polymorphic DLBCL Burkitt/Plasma Cell T cell Classic Hodgkin Total
Patients 16 30 3 5 6 60
Age at transplant 
(years ± SD)
12.98 ± 17.16 27.78 ± 22.90 15.23 ± 25.78 40.66 ± 23.43 28.57 ± 17.35
Age at transplant under 
21 years 
14 (87.5) 16 (53.33) 2 (66.67) 1 (20) 2 (33.33) 35
Male 11 (68.75) 16 (53.33) 2 (66.67) 3 (60) 4 (66.67) 36
Subject deatha 6 (37.5) 14 (46.67) 1 (33.33) 4 (80) 1 (16.67) 26
Death‐censored graft failurea 2 (12.5) 2 (6.67) 0 (0) 0 (0) 1 (16.67) 5
Organ transplant type 16 30 3 5 6 60
Kidney 3 (18.75) 5 (16.67) 0 (0) 3 (60) 4 (66.67) 15
Liver 0 (0) 5 (16.67) 0 (0) 0 (0) 0 (0) 5
Heart 2 (12.5) 6 (20) 1 (33.33) 0 (0) 0 (0) 9
Lung 9 (56.25) 11 (36.67) 2 (66.67) 2 (40) 1 (16.67) 25
Bone marrow 1 (6.25) 0 (0) 0 (0) 0 (0) 1 (16.67) 2
Multiple 1 (6.25) 3 (10) 0 (0) 0 (0) 0 (0) 4
Median months from 
transplant to PTLD (Q1, Q3)
37 (6, 69) 28.5 (7, 127) 97 (85, 145) 132 (57, 164) 116 (102, 199)
Sample location 18 34 5 6 6 69
Lymph node 7 (38.89) 4 (11.76) 1 (20) 1 (16.67) 6 (100) 19
GI tract 1 (5.56) 14 (41.18) 5 (100) 1 (16.67) 0 (0) 21
Liver 1 (5.56) 5 (14.71) 0 (0) 0 (0) 0 (0) 6
CNS 0 (0) 2 (5.88) 0 (0) 1 (16.67) 0 (0) 3
Disseminated 1 (5.56) 3 (8.82) 1 (20) 3 (50) 1 (16.67) 9
Bone Marrow 1 (5.56) 0 (0) 0 (0) 2 (33.33) 0 (0) 3
Lung 2 (11.11) 6 (17.65) 0 (0) 0 (0) 0 (0) 8
Other 7 (38.89) 6 (17.65) 0 (0) 3 (50) 0 (14.29) 16
Numbers in parentheses indicate percentages. DLBCL, diffuse large B cell lymphoma.
aSubject death and death‐censored graft failure were assessed within 5 years of the diagnosis of PTLD. 
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according to the described criteria. The male: female ratio 
was 36:24. The median age of the subjects was 15.1 years 
(range 0.1 to 67.9 years; mean 22.7, <21 years at time of 
transplant = 35/60). Subjects with polymorphic PTLD were 
younger at transplant (median age 13.0 years) than other 
groups, while the subjects with T cell PTLD were older 
at transplant (median age 40.7 years) than other groups 
(Table 1).
The transplanted organ was distributed across all the 
major types, lung being the most common (Table 1). 
PTLD was located in diverse locations, lymph node and GI 
tract being the most common. Applying the World Health 
Organization (WHO) classification of PTLD,26,27 our 69 tis-
sue cases were mostly monomorphic B cell type in 39 (of 
which 34 were DLBCL and five were other types). For the 8 
subjects who had more than 1 PTLD occurrence (one subject 
had two recurrences), the PTLD WHO type was the same in 
each occurrence, except in one subject, who had a Hodgkin 
type PTLD initially and a DLBCL type in the recurrence 
3 years later.
Death‐censored graft failure occurred in 8/60 (six in 
patients who later died) at a median time of 3.2 years after 
PTLD diagnosis (IQR 0.6‐7.2 years). Of the eight graft fail-
ures, five grafts failed within 5 years of the PTLD diagnosis. 
Thirty‐two patients had died at the time the samples were 
analyzed, at a median time of 3.5 years after PTLD diagnosis 
(IQR 0.7‐8.1 years, range 0–18.8 years). Of the 32 deaths, 26 
died within 5 years of the PTLD diagnosis.
3.2 | Detection of viral nucleotide sequences 
by MSS
Nucleotide sequences from at least one virus were detected 
by MSS in 86% (59/69) of the sequenced PTLD samples. 
Figure 1 depicts the viral sequences detected. EBV was 
detected in 61% (42/69) of the PTLD samples, and it was 
also detected in all of the 4 EBV positive control samples 
but not in any of the eight negative controls. Of the single‐
stranded DNA viruses, anelloviruses were detected in 52% of 
the PTLD samples. Positivity by MSS for a viral genus was 
handled as a categorical yes/no variable in further analyses. 
When correlating with WHO classification, all six Hodgkin 
lymphoma cases were EBV sequencing positive and 5/6 were 
roseolovirus positive while all six T cell PTLDs were EBV 
sequencing negative (see Figure 1 for breakdown according 
to WHO PTLD type and see Figure S1). Anellovirus positiv-
ity by MSS did not associate with PTLD WHO type (Figure 
S1).
3.3 | EBV genome variants
We had >70% of the EBV genome length represented in 
the sequence data from samples from 37 unique PTLD 
patients, 33 EBV‐1 and 4 EBV‐2. The 33 EBV‐1 sam-
ples were used for subsequent comparative analysis. We 
chose to focus on nine specific EBV genes that are most 
associated with oncogenesis or with viral latency pro-
files.2 We determined the nucleotide variants in each of 
these nine genes and classified variants as synonymous 
(no change in the predicted amino acid coding) vs non-
synonymous (predicted change in the amino acid coding, 
and therefore more likely to be pathogenic). As shown in 
Table 2, the genes EBNA3C, EBNA‐LP, and LMP1 had 
a greater ratio of nonsynonymous changes to synony-
mous changes, suggesting a greater chance of pathogenic 
variants within these genes. Logistic regression analyses 
showed that the genes with the highest percent nonsyn-
onymous changes were EBNA‐LP (significantly higher 
than all other genes), and EBNA1 and EBNA3C (signifi-
cantly lower than EBNA‐LP but significantly higher than 
all other genes; Figure 2).
3.4 | MSS viral genome detection in EBV‐
negative PTLD
The distribution of the different viruses in the EBV‐negative 
PTLD tissues is shown in Figure 1 and is further described in 
Supplementary Results.
F I G U R E  1  DNA viruses detected in stored PTLD tissues, 
stratified by WHO type. Each row represents a different sequenced 
sample. Viruses are noted in columns. A dark bar indicates the virus 
was detected in that sample, and gray background indicates the virus 
was not detected
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3.5 | Comparison of EBV and anellovirus 
detection methods
We confirmed that our tissue MSS results for EBV and an-
ellovirus by quantitative tissue PCR. TTV levels by PCR 
were significantly higher in samples that were positive for 
anellovirus by MSS, compared to those that were negative by 
MSS (P < 0.001, data not shown). Copy loads for EBV and 
TTV by PCR showed a modest but significant association 
with each other (Pearson correlation coefficient rho = 0.36, 
P < 0.001, data not shown).
3.6 | Survival analysis (patient death)
3.6.1 | Contingency analyses
We first analyzed for survival outcomes in relation to MSS 
or qPCR results by using contingency analyses (Table S1). 
Patient death within 5 years of PTLD diagnosis was associated 
with anellovirus (30% dead if negative vs 57% dead if positive; 
P = 0.037) and gammapapillomavirus (38% dead if negative 
and 86% dead if positive; P = 0.036) positivity by MSS. Death 
was not associated with EBV positivity (any method–clinical 
tumor positivity, MSS or PCR positivity), WHO classification 
type or early vs late onset PTLD. The only clinical parameter 
to associate with higher patient death in contingency analyses 
was liver location of PTLD (P = 0.031). Anellovirus tissue 
MSS positivity did not associate with PTLD WHO type, any 
specific location of PTLD or age at transplant.
3.6.2 | Tissue qPCR
We also analyzed the relationship between patient presenta-
tion or survival and levels of EBV and TTV measured by 
qPCR. Neither EBV PCR copy number nor TTV PCR copy 
number was associated with PTLD WHO type (data not 
shown). EBV PCR copy load did not associate with patient 
death (Figure 3A). In contrast, TTV PCR loads were signifi-
cantly higher in patients who died (P = 0.032; Figure 3B). 
The median TTV copy number was 122 in the overall cohort 
and was 931 in patients who died within 5 years of PTLD 
diagnosis (vs 21 in those still alive at 5 years). Patient death 
occurred in 72% of those with TTV tissue load above the 
median of 122, whereas patient death was only 43% for those 
with TTV loads below the median (P = 0.024).
3.6.3 | Time to event analyses
We then analyzed covariate associations to patient death 
within 5 years of PTLD diagnosis using time‐to‐event analy-
ses (Table 3). Univariable Cox regression analyses revealed 
that, liver, CNS or bone marrow locations of PTLD were 
significantly associated with worse patient survival. MSS 
positivity for anelloviridae (HR 2.00, 95% CI 0.09, 4.70, 
P = 0.09) and gammapapillomavirus (HR 2.38, 95% CI 
0.87, 5.62, P = 0.06) trended toward worse patient survival. 
In subset sensitivity analyses where T cell PTLD was ex-
cluded, anellovirus positivity by MSS was significantly as-
sociated with patient death within 5 years of PTLD diagnosis 
(Supplementary Results).
A quantified TTV PCR load greater than the median of 
122 copies/μg human DNA also trended with higher patient 
death (HR 2.23, 95% CI 0.98, 5.51, P = 0.058). Notably, 
the log‐transformed TTV viral load was strongly associated 
with patient death (hazard ratio 1.10, 95% confidence in-
tervals 1.02, 1.20, P = 0.016), suggesting that higher tissue 
anellovirus quantity has a dose‐response relationship with 
patient death.
In contrast, EBV positivity by any method, including 
log‐transformed copy number, did not associate with patient 
F I G U R E  2  Plots of adjusted percent nonsynonymous sequence changes (nonsynonymous*100/nonsynonymous + synonymous + no change) 
in EBV genes, with 95% confidence intervals, as calculated by logistic regression analysis that included a random effect to adjust for repeated 
measurements. Differently colored and/or patterned lines correspond to significantly different genes (Tukey adjustment)
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death in time‐to‐event (Table 3) or sensitivity analyses 
(Supplementary Results).
3.6.4 | Multivariable analyses
Finally, based on our univariate associations and known lit-
erature, we fitted a multivariate Cox regression model where 
4 variables were considered for inclusion: age at transplant, 
T cell PTLD, log‐transformed EBV PCR copy number, log‐
transformed TTV PCR copy number. Only T cell type PTLD 
(adjusted hazard ratio 4.14; 95% confidence intervals 1.18, 
11.28, P = 0.006) and log‐transformed TTV PCR copy num-
ber (adjusted hazard ratio 1.11; 95% confidence intervals 
1.02, 1.20, P = 0.012) remained independently significant.
4 |  DISCUSSION
In this study, we were able to successfully recover multiple 
DNA viral genomes from stored FFPE tissue, identify viruses 
in sequence data, and assess for sequence variants in key 
EBV genes. A key strength of our study was the broad range 
of viruses detectable, made possible by using a sequencing 
approach rather than a targeted PCR‐based approach. We are 
able to achieve a high degree of coverage of the EBV genome 
and detected many variants, across all the nine EBV genes 
tested. Certain EBV genes had higher percentages or propor-
tions of nonsynonymous nucleotide variants.
Data on the genomic diversity of EBV and their contribu-
tion to PTLD pathogenesis or outcomes are scant, with small 
sample sizes in all, given the rarity of this disease. Vaysberg 
et al, from a panel of five EBV+ B cell lymphomas, iden-
tified three distinct and different variants of LMP1, with 2 
gain of function mutations, which induced sustained MAP 
kinase activation and c‐Fos induction.28 Notably, we detected 
one of these gain of function mutations, S366T, in three of 
our polymorphic PTLD samples. Using FFPE tissues, Nourse 
et al found that EBV‐miRNA was profiled reliably within ar-
chival FFPE tissue in 14/23 patients, but not in tissues with 
low abundance of EBV.29 In subsequent studies, the same 
group found that nine CNS and 16 systemic PTLD tissues 
expressed similar viral latent (EBNA2, EBNA3A, LMP1) and 
lytic (BZLF1, BRLF1, BLLF1) gene mRNA transcripts.30
From studies of other EBV‐associated cancers in a non-
transplant setting in a general population, the genes BRLF1, 
BBRF3, and BBLF2/BBLF3 had significant associations with 
gastric carcinoma.31 In Argentina, investigators detected an 
association between specific BZLF1 gene variants such as 
BZLF1‐A2 with lymphomas and BZLF1‐C with infectious 
mononucleosis.32 Specific polymorphisms in two viral gene 
promoters Cp and Qp were found in nasopharyngeal carci-
noma.33 A clonal LMP1 gene containing a 30 bp deletion 
(del30) was found in 46.1% of NK/T cell lymphomas and 
only in 4.8% of the controls, with much worse patient survival 
in those with this deletion.34 However, as shown in endemic 
Burkitt lymphoma, within a geographic region, different 
EBV genetic variations can coexist,35 such that specific gene 
variation associations with presentation or prognosis have 
been difficult. Although our study was not powered to detect 
individual variants associated with survival or PTLD type, 
F I G U R E  3  Results of EBV or TTV quantitative PCR vs 
patient survival after PTLD. (A) Box and whiskers plot of EBV tissue 
PCR (copies/μg human DNA), stratified by patient alive or dead at 
5 years after PTLD diagnosis (P = NS). (B) Box and whisker plot 
of TTV tissue PCR (copies/μg human DNA), where higher TTV 
qPCR loads were present in patients dead at 5 years after PTLD 
diagnosis (P = 0.032). The Y‐axis is shown on log base 10 scale. 
Values below detection limit were assigned a value of 0.00001. Data 
points correspond to the SAMPLES (there can be >1/subject), and 
are “jittered” so that samples with overlapping markers are separated 
from each other. Box‐plot characteristics: Line = Median, Top edge 
of box = 75th percentile (Q3), Bottom edge of box = 25th percentile 
(Q1), Upper and lower whiskers = 1.5 × IQR (Q3‐Q1)
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T A B L E  3  Univariable Cox regression analysis of relationship of covariates with patient death within 5 years of PTLD diagnosis
Variable Reference group Hazard Ratio (95% CI) P‐value
Age at transplant (Years) Each 1 year age increment 1.01 (0.99, 1.03) 0.18
Male Female 0.97 (0.45,2.17) 0.94
Transplant type
Heart Bone marrow 0.33 (0.04,6.86) 0.85
Liver Bone marrow 0.78 (0.10,15.98)
Lung Bone marrow 0.55 (0.10,10.15)
Multi‐organ Bone marrow 0.58 (0.05,12.71)
Kidney Bone marrow 0.40 (0.06,7.69)
Locations of PTLD
Lymph node Non‐lymph node location 0.45 (0.15,1.09) 0.10
GI tract Non‐GI tract location 0.87 (0.34,1.97) 0.74
Liver Non‐liver location 4.15 (1.20,11.17) 0.005
CNS Non‐CNS location 6.74 (0.36,36.73) 0.037
Bone Marrow Non‐bone marrow location 14.74 (2.99,61.04) <.001
Lung Non‐lung location 0.43 (0.07,1.47) 0.24
Time from transplant to PTLD
1 year or above <1 year 0.81 (0.37,1.90) 0.61
PTLD type
Polymorphic Non‐polymorphic 0.66 (0.24,1.54) 0.36
DLBCL Non‐DLBCL 1.25 (0.58,2.76) 0.57
Classic Hodgkin Non‐Hodgkin 0.35 (0.02,1.64) 0.28
T cell Non‐T cell 3.58 (1.04,9.40) 0.013
Burkitt lymphoma/plasma cell Non‐Burkitt/Plasma 0.74 (0.04,3.48) 0.76
Induction immunosuppression Regimen^ other Anti‐thymocyte globulin 0.87 (0.29,2.87) 0.22
Unknown Anti‐thymocyte globulin 0.55 (0.15,1.97)
Anti‐IL2 receptor Anti‐thymocyte globulin 1.74 (0.56,5.89)
Log TTV copies/μg of Human DNA* Each 1 log increase 1.10 (1.02,1.20) 0.016
TTV‐ copies/μg of Human DNA: >median* TTV‐1 copies/μg of Human DNA: ≤ median 2.23 (0.98,5.51) 0.058
Tumor EBV status (clinical testing) Any Positive@ Negative 0.55 (0.25,1.27) 0.14
Log EBV copies/μg of Human DNA* Each 1 log increase 1.01 (0.93, 1.11) 0.76
EBV copies/μg of Human DNA: > median* EBV copies/μg of Human DNA: ≤ median 1.28 (0.57,2.97) 0.55
MSS positive
EBV Negative 0.67 (0.31,1.47) 0.30
Cytomegalovirus Negative 0.52 (0.03,2.47) 0.51
HHV6 or 7 Negative 1.15 (0.52,2.49) 0.73
Simplexvirus Negative 2.45 (0.14,11.84) 0.37
BK_polyomavirus Negative 4.76 (0.26,24.46) 0.10
Merkel_cell_polyoma Negative 0.52 (0.03,2.48) 0.52
Alphapapillomavirus Negative 1.05 (0.06,4.94) 0.97
Betapapillomavirus Negative 1.75 (0.68,4.00) 0.20
Gammapapillomavirus Negative 2.38 (0.87,5.62) 0.06
Papillomaviridae Negative 1.85 (0.44,5.32) 0.31
Erythroparvovirus Negative 0.76 (0.12,2.54) 0.70
Anelloviridae Negative 2.00 (0.91,4.70) 0.09
Number dead within 5 years = 26 and number alive at 5 years post‐PTLD = 34, except where marked separately.
^Number dead = 25, number alive = 34, *Number dead = 24, number alive = 33, @Number dead = 25, number alive = 30.
For log‐transformed PCR values, 1 was added to all values to account for PCR copy number = 0, as log 0 is not defined and log 1 = 0.
PTLD locations were not mutually exclusive.
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we have demonstrated the technology can be successfully 
be used for this approach. The significance of specific EBV 
variants should be explored in future multicenter studies.
Prior studies of EBV‐negative DLBCL PTLD cases 
(n = 9) have shown that human gene alterations in these cases 
are more similar to those seen in immunocompetent Hodgkin 
lymphoma or non‐Hodgkin lymphoma, rather than the human 
gene alterations seen in EBV‐positive PTLDs (n = 24).36,37 
These results suggested that viral oncogenesis is not a key 
pathological pathway in EBV‐negative DLBCL PTLD. Our 
results, where no DNA viral genus was overrepresented in 
EBV‐negative PTLD tissue samples, would support this hy-
pothesis, though our larger sample size of 27 EBV‐negative 
PTLDs is also relatively small.
While we are not aware of any reported association be-
tween gammapapillomavirus and degree of overall immu-
nosuppression, the association of anellovirus positivity with 
patient death in our exploratory analyses was of particular 
interest. The biological significance of the entire anello-
virus group is unknown and evolving.38,39 Using cell‐free 
DNA sequencing from plasma samples derived from tho-
racic organ transplant recipients, De Vlaminck et al40 found 
a marked expansion of the annelloviridae family upon the 
onset of immunosuppression and a lower AnV burden with 
acute rejection episodes, even with appropriate drug immu-
nosuppression levels. Blatter et al found that low AnV loads 
in pediatric lung transplant recipients at 2 weeks posttrans-
plantation were more likely to develop acute rejection within 
3 months after transplant (P = 0.013).41 High Anv loads 
from broncholaveolar lavage samples in lung transplant pa-
tients correlated with dysbiotic bacterial communities in the 
allograft. 42 In adult kidney transplantation, low levels of 
AnV associated with higher risk of late acute antibody‐me-
diated rejection.43 These findings suggest that anelloviruses 
can be a biomarker for the overall degree of immunosuppres-
sion achieved.40
Strengths of our study include demonstrating the feasibil-
ity of MSS of old, stored FFPE tissue for detection of viral 
genomes, the use of actual human PTLD specimens rather 
than in vitro cell lines to investigate for EBV variants, and 
the possible association with clinical presentations and out-
comes. Limitations of the study include its single center and 
retrospective nature. Determining which microbial gene vari-
ants are pathogenic is more challenging than with human 
gene variants. In the latter, many resources are available to 
help determine pathogenicity, such as well‐annotated refer-
ence genomes, published literature on mutants that are asso-
ciated with clinical pathology, and prediction models. Such 
tools are not as well‐developed for most microbial genome 
variants. An additional limitation of the MSS technology is its 
analysis of samples for short genomic reads, which may miss 
larger deletions. The fragmented nature of nucleic acid from 
FFPE tissue also compounds the difficulty in distinguishing 
true deletions from missing sequence coverage. For our MSS 
results, we emphasized specificity over sensitivity; our strict-
ness in calling a sample positive may have been too stringent. 
EBV is the driver for PTLD onset,2,44-46 thus other agents may 
act in the modulation of disease progression. Finally, patient 
survival can be very different in different organ transplants 
with different locations or WHO types of PTLD. We have ac-
counted for WHO type; T cell PTLD remained independently 
significant in multivariate models, consistent with other re-
cent reports.47 Certain individual locations were associated 
with higher risk of patient death in univariate analyses in our 
study, but each was present in very few subjects. Individual 
organ transplant type was not a significant univariate predic-
tor in our study population. Notably, the prior PTLD‐1 trial 
evaluated survival after a common treatment regimen across 
different organ transplants and different WHO types. A com-
pletely homogenous PTLD study population is not possible 
given the relative rarity of this disease. Immunosuppression 
regimen associations were difficult to assess given the long 
time period when samples were acquired and the variety of 
regimens across organs.
In future, we expect to characterize further the specific types 
of EBV variants (single nucleotide variants, insertions, dele-
tions, missense mutations, etc.) in the nine EBV genes we have 
analyzed so far. We will also expand our analyses to other EBV 
genes, using a larger cohort for greater power. Future studies 
could also involve laser capture of single malignant PTLD cells 
from tissue, and single cell RNA sequencing, but our study is 
the necessary first step.
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